专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US09526777B2 Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein 有权
标题翻译：用于诱导埃博拉病毒特异性免疫应答的方法，包括给予表达埃博拉病毒糖蛋白的复制缺陷型黑猩猩腺病毒载体
公开(公告)号：US09526777B2
公开(公告)日：2016-12-27
申请号：US13641655
申请日：2011-04-15
申请人： Nancy J. Sullivan , Gary J. Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
发明人： Nancy J. Sullivan , Gary J. Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
IPC分类号： A61K39/295 , A61K39/12 , A61K39/00
CPC分类号： C12N15/86 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N2710/10343 , C12N2760/14134
摘要： This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).
摘要翻译：本发明提供用于诱导免疫应答的疫苗和针对用于人类预防性疫苗的禽流感病毒感染的保护。特别地，本发明提供了表达来自埃博拉病毒（EBOV）或马尔堡病毒（MARV）的不同菌株的病毒蛋白的黑猩猩腺病毒载体。

12. 发明授权

US07598362B2 Hepatitis C virus vaccine 有权
标题翻译：丙型肝炎病毒疫苗
公开(公告)号：US07598362B2
公开(公告)日：2009-10-06
申请号：US10492178
申请日：2002-10-10
申请人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
发明人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
IPC分类号： C07H21/04 , C12N7/00
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
摘要翻译：本发明的特征在于Ad6载体和编码含有非活性NS5B RNA依赖性RNA聚合酶区域的Met-NS3-NS4A-NS4B-NS5A-NS5B多肽的核酸。核酸特别可用作腺病毒或DNA质粒疫苗的组分，其提供用于产生针对HCV的HCV特异性细胞介导的免疫（CMI）应答的广泛范围的抗原。

13. 发明申请

US20090233992A1 HEPATITIS C VIRUS VACCINE 有权
公开(公告)号：US20090233992A1
公开(公告)日：2009-09-17
申请号：US12396747
申请日：2009-03-03
申请人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloen
发明人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloen
IPC分类号： A61K31/7088
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
摘要翻译：本发明的特征在于Ad6载体和编码含有非活性NS5B RNA依赖性RNA聚合酶区域的Met-NS3-NS4A-NS4B-NS5A-NS5B多肽的核酸。核酸特别可用作腺病毒或DNA质粒疫苗的组分，其提供用于产生针对HCV的HCV特异性细胞介导的免疫（CMI）应答的广泛范围的抗原。

14. 发明申请

US20050019751A1 Screening for hepatitis c virus entry inhibitors 审中-公开
标题翻译：筛查丙型肝炎病毒进入抑制剂
公开(公告)号：US20050019751A1
公开(公告)日：2005-01-27
申请号：US10494555
申请日：2002-11-01
申请人： Riccardo Cortese , Elisa Scarselli , Alessandra Vitelli
发明人： Riccardo Cortese , Elisa Scarselli , Alessandra Vitelli
IPC分类号： A61K39/395 , A61K45/00 , A61P1/16 , A61P31/14 , C07H21/04 , C07K1/00 , C07K14/00 , C07K17/00 , C12N15/09 , C12Q1/02 , C12Q1/70 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/576
CPC分类号： G01N33/5767 , G01N2333/18 , G01N2500/02
摘要： The present invention features methods of screening for compounds that inhibit HCV binding to a cell, methods of inhibiting IICV entry into a cell, and methods of actively or prophylactically treating against an IICV infection. The different methods are based on the identification of the scavenger receptor class B type I as a target site for HCV E2 binding to a cell.
摘要翻译：本发明的特征在于筛选抑制HCV结合细胞的化合物的方法，抑制IICV进入细胞的方法，以及主动或预防性治疗IICV感染的方法。不同的方法基于识别作为HCV E2与细胞结合的靶位点的B型清道夫受体。

15. 发明授权

US5994083A Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable 失效
公开(公告)号：US5994083A
公开(公告)日：1999-11-30
申请号：US553257
申请日：1995-11-13
申请人： Franco Felici , Alessandra Luzzago , Paolo Monaci , Alfredo Nicosia , Riccardo Cortese
发明人： Franco Felici , Alessandra Luzzago , Paolo Monaci , Alfredo Nicosia , Riccardo Cortese
IPC分类号： G01N33/53 , A61K35/76 , A61K39/00 , C07K7/08 , C07K14/02 , C07K14/18 , C07K14/47 , C07K16/32 , C09K8/38 , C12N7/00 , C12N15/09 , C12N15/10 , C40B30/06 , C40B40/02 , G01N33/569 , G01N33/576 , G01N33/537 , G01N33/566
CPC分类号： C40B40/02 , C07K14/005 , C07K14/4713 , C07K16/32 , C12N15/1037 , A61K39/00 , C07K2319/40 , C07K2319/735 , C12N2730/10122 , C12N2770/24222 , Y10S436/811
摘要： A process for the preparation of immunogens or diagnostic reagents that mimic an antigen or a pathogenic organism specific to a disease, essentially characterized by the following operations: identification of at least one antibody that reacts with the antigen or pathogenic organism specific to the disease; construction of phage libraries which display on the surface of the capsid oligopeptides, expressed from random sequence oligonucleotidic inserts introduced into a gene coding for a phage capsid protein using genetic manipulation techniques (for example using a plasmid engineered for the purposes of the invention, the genetic map of which is shown in the figure); selection of the phages that display on the surfaces of the capsid antigenic oligopeptides recognized by said antibody; optional use of the selected phages and/or fragments thereof and/or their derivatives for the formulation of diagnostic kits for the specific pathogenic agent, or in general for the diseases, including immunological disorders typical of so-called autoimmune diseases, with known or unknown etiology and/or pathogenesis; optional use of the selected phages and/or fragments thereof and/or their derivatives for the formulation of an antagonist ofthe antigen-antibody reactions for treatment of the disease induced by said antigen; optional use of the selected phages and/or fragments thereof and/or their derivatives to induce a tolerance of the phenomena of hypersensitivity and/or allergy to compounds and/or natural or synthetic preparations; optional immunization of an organism by means of the selected phages and/or fragments thereof and/or their derivatives; and optional verification of the presence, in the serum of the immunized organism, of antibodies that recognize the above antigen or organism specific to the disease.

16. 发明授权

US08142794B2 Hepatitis C virus vaccine 有权
标题翻译：丙型肝炎病毒疫苗
公开(公告)号：US08142794B2
公开(公告)日：2012-03-27
申请号：US12396747
申请日：2009-03-03
申请人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
发明人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
IPC分类号： C12N7/00 , C07H21/04
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
摘要翻译：本发明的特征在于Ad6载体和编码含有非活性NS5B RNA依赖性RNA聚合酶区域的Met-NS3-NS4A-NS4B-NS5A-NS5B多肽的核酸。核酸特别可用作腺病毒或DNA质粒疫苗的组分，其提供用于产生针对HCV的HCV特异性细胞介导的免疫（CMI）应答的广泛范围的抗原。

17. 发明申请

US20120027788A1 SIMIAN ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF 有权
标题翻译： SIMIAN ADENOVIRUS核酸和氨基酸序列，含有它们的载体及其用途
公开(公告)号：US20120027788A1
公开(公告)日：2012-02-02
申请号：US13147193
申请日：2010-02-06
申请人： Stefano Colloca , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Maria Ambrosio
发明人： Stefano Colloca , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Maria Ambrosio
IPC分类号： A61K39/235 , C12N15/57 , C07K14/075 , C12N15/63 , A61P37/04 , A61K48/00 , C12N1/21 , C12N1/19 , C12N5/10 , A61P31/20 , C12N15/34 , C12N7/01
CPC分类号： C07K14/005 , A61K39/0011 , A61K39/12 , A61K39/235 , A61K48/00 , A61K2039/525 , A61K2039/5256 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10322 , C12N2710/10334 , C12N2710/10343 , C12N2710/16634 , C12N2740/16134 , C12N2770/24234
摘要： The present invention relates to novel adenovirus strains with an improved sero-prevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
摘要翻译：本发明涉及具有改善的血清流行性的新型腺病毒株。一方面，本发明涉及腺病毒衣壳蛋白如六邻体，五邻体和纤维蛋白及其片段的分离多肽和编码该多肽的多核苷酸。还提供了包含根据本发明的分离的多核苷酸和包含根据本发明的分离的多核苷酸或多肽的腺病毒的载体和包含所述载体，腺病毒，多肽和/或多核苷酸的药物组合物。本发明还涉及分离的多核苷酸，分离的多肽，载体，腺病毒和/或药物组合物用于治疗或预防疾病的用途。

18. 发明申请

US20070259959A1 Ppar Agonists for the Treatment of Hcv Infection 审中-公开
标题翻译： Ppar激素治疗Hcv感染
公开(公告)号：US20070259959A1
公开(公告)日：2007-11-08
申请号：US10579509
申请日：2004-11-17
申请人： Riccardo Cortese , Alfredo Nicosia , Alessandra Vitelli
发明人： Riccardo Cortese , Alfredo Nicosia , Alessandra Vitelli
IPC分类号： A61K31/192 , A61P31/12
CPC分类号： A61K31/216
摘要： The present invention concerns the use of PPARα agonists in methods and compositions for the treatment or prevention of infection by hepatitis C virus (HCV) in mammals, especially humans.
摘要翻译：本发明涉及PPARα激动剂在用于治疗或预防哺乳动物，特别是人类中丙型肝炎病毒（HCV）感染的方法和组合物中的用途。

19. 发明申请

US20140141042A1 Expression Systems 审中-公开
标题翻译：表达系统
公开(公告)号：US20140141042A1
公开(公告)日：2014-05-22
申请号：US13976873
申请日：2011-12-30
申请人： Alessandra Vitelli , Alfredo Nicosia , Riccardo Cortese
发明人： Alessandra Vitelli , Alfredo Nicosia , Riccardo Cortese
IPC分类号： C12N15/85
CPC分类号： A61K39/145 , A61K39/12 , A61K39/155 , A61K2039/53 , C07K14/005 , C12N15/85 , C12N15/86 , C12N2710/10343 , C12N2760/18522 , C12N2760/18534 , C12N2800/22 , C12N2840/20
摘要： The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture. The expression system, polynucleotides, proteins, cells, and pharmaceutical compositions are useful in the prophylaxis or treatment of infections. The invention further relates to nucleotide constructs which comprises, essentially consists or consists of a polynucleotide encoding a modified influenza hemagglutinin (HA).
摘要翻译：本发明涉及包含编码蛋白质的多核苷酸的表达系统，其中所述表达系统包含编码诱导T细胞应答的至少一种蛋白质，肽或变体的第一多核苷酸，以及编码至少一种蛋白质肽或变体的第二多核苷酸其诱导抗致病性B细胞应答。本发明还涉及由表达系统编码的蛋白质混合物和包含表达系统或蛋白质混合物的细胞和包含表达系统或蛋白质混合物的药物组合物。表达系统，多核苷酸，蛋白质，细胞和药物组合物可用于预防或治疗感染。本发明还涉及核苷酸构建体，其包含，基本上由编码经修饰的流感血凝素（HA）的多核苷酸组成或组成。

20. 发明申请

US20130101618A1 CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES 有权
标题翻译： CHIMPANZEE腺病毒载体的FILOVIRUS疫苗
公开(公告)号：US20130101618A1
公开(公告)日：2013-04-25
申请号：US13641655
申请日：2011-04-15
申请人： Nancy J. Sullivan , Gary J. Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
发明人： Nancy J. Sullivan , Gary J. Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
IPC分类号： A61K39/12
CPC分类号： C12N15/86 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N2710/10343 , C12N2760/14134
摘要： This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
摘要翻译：本发明提供用于诱导免疫应答的疫苗和针对用于人类预防性疫苗的禽流感病毒感染的保护。特别地，本发明提供了表达来自不同的埃博病毒（EBOV）或马尔堡病毒（MARV）病毒的病毒蛋白的黑猩猩腺病毒载体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式